Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Department of Medicine III, University Hospital – LMU Munich, Munich, Germany; Hematopathology Section, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Department of Hematology, Imagine Institute and Descartes University, INSERM U1163 and CNRS ERL 8564, Necker Hospital, Paris, France; Department of Hematology, University Lund, Lund, Sweden; CHU de Nantes, Service d’Hématologie Clinique, Université de Nantes, Nantes, France; Peninsula School of Medicine and Dentistry, University of Plymouth, Plymouth, UK; Institute of Hematology, Assuta Medical Center, Tel-Aviv, Israel; Department of Lymphoid Malignancy, Maria Sklodowska-Curie Institute and Oncology Centre, Warsaw, Poland; Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

[1]  L. Gordon.  Faculty Opinions recommendation of Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[2]  T. Kipps,et al.  Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Pileri,et al.  Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. , 2017, The Lancet. Haematology.

[4]  M. Dreyling,et al.  Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results , 2016 .

[5]  M. Ghielmini,et al.  Maintenance Therapy for Patients with Mantle Cell Lymphoma (MCL) - a Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs) , 2016 .

[6]  G. Salles,et al.  Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group , 2016 .

[7]  E. Kimby,et al.  15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau , 2016, British journal of haematology.

[8]  A. Rosenwald,et al.  Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Klapper,et al.  Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network , 2016, The Lancet.

[10]  W. Klapper,et al.  Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials , 2016, Leukemia.

[11]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[12]  T. Berg,et al.  Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). , 2016, The Lancet. Infectious diseases.

[13]  J. Radford,et al.  Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. , 2016, The Lancet. Oncology.

[14]  Nibedita Bandyopadhyay,et al.  Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study , 2016, The Lancet.

[15]  W. Hiddemann,et al.  Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial , 2013, Leukemia.

[16]  Michael L. Wang,et al.  Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[17]  Sonali M. Smith,et al.  Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. , 2015, The New England journal of medicine.

[18]  F. Cavalli,et al.  Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. , 2015, The New England journal of medicine.

[19]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Kimby,et al.  The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma , 2014, Leukemia.

[21]  J. Byrd,et al.  A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). , 2014, Blood.

[22]  J. Burke,et al.  Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. , 2014, Blood.

[23]  M. Jerkeman,et al.  High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial , 2014, Leukemia & lymphoma.

[24]  G. Behre,et al.  Allogeneic stem cell transplantation for mantle cell lymphoma—final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO) , 2014, Annals of Hematology.

[25]  M. Dreyling.  Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[26]  R. Bouabdallah,et al.  Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC , 2014, Annals of Hematology.

[27]  A. Roberts,et al.  The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients , 2013 .

[28]  W. Klapper,et al.  Role Of High-Dose Cytarabine and Total Body Irradiation Conditioning before Autologous Stem Cell Transplantation In Mantle Cell Lymphoma - A Comparison Of Nordic MCL2, HOVON 45, and European MCL Younger Trials , 2013 .

[29]  J. Drach,et al.  Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Vose,et al.  Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  G. Salles,et al.  Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[33]  Shou-Dong Lee,et al.  Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Giné,et al.  Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  L. Rimsza,et al.  A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  M. Stauch,et al.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.

[37]  G. Pizzolo,et al.  Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  G. Salles,et al.  CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. , 2013, Blood.

[39]  D. Maloney,et al.  Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  E. Macintyre,et al.  Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study , 2012 .

[41]  R. Advani,et al.  Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  W. Klapper,et al.  Treatment of older patients with mantle-cell lymphoma. , 2012, The New England journal of medicine.

[43]  E. Kimby,et al.  Nordic MCL2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur , 2012, British journal of haematology.

[44]  P. Mclaughlin,et al.  Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. , 2012, The Lancet. Oncology.

[45]  M. Ghielmini,et al.  A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma , 2012, Haematologica.

[46]  B. Sander,et al.  Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. , 2012, Blood.

[47]  S. Pileri,et al.  Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers , 2012, Haematologica.

[48]  F. Angrilli,et al.  Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi , 2012, British journal of haematology.

[49]  M. Dreyling,et al.  Treatment of younger patients with mantle cell lymphoma. , 2011, Seminars in hematology.

[50]  A. Chott,et al.  Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma , 2011, Haematologica.

[51]  A. Feldman,et al.  Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. , 2011, The Lancet. Oncology.

[52]  P. Korkolopoulou,et al.  Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen , 2011, Leukemia & lymphoma.

[53]  R. Gascoyne,et al.  A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172) , 2011, Leukemia & lymphoma.

[54]  J. Rossi,et al.  Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group , 2010, Haematologica.

[55]  J. Leonard,et al.  Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma , 2010, Cancer.

[56]  W. Klapper,et al.  Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. , 2010, Blood.

[57]  A. Rosenwald,et al.  Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. , 2010, Cancer research.

[58]  J. Byrd,et al.  Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  E. Hoster,et al.  Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma. , 2009 .

[60]  Michael L. Wang,et al.  Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  L. Staudt,et al.  SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype , 2009, Haematologica.

[62]  B. Coiffier,et al.  Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Jeroen van der Laak,et al.  Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network , 2009, Journal of hematopathology.

[64]  J. Leonard,et al.  Outcome of deferred initial therapy in mantle-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  A. Hagenbeek,et al.  High‐dose Ara‐C and beam with autograft rescue in R‐CHOP responsive mantle cell lymphoma patients , 2009, British journal of haematology.

[66]  J. Leonard,et al.  Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[67]  D. Moore,et al.  Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma , 2008, Cancer.

[68]  Martin Dreyling,et al.  A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.

[69]  G. Schwarzer,et al.  Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. , 2007, Journal of the National Cancer Institute.

[70]  W. Hiddemann,et al.  Clinical Trials and Observations , 2005 .

[71]  M. Boccadoro,et al.  Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[72]  N. Willich,et al.  Follicular lymphoma, immunocytoma, and mantle cell lymphoma: Randomized evaluation of curative radiotherapy in limited stage nodal disease , 2006 .

[73]  L. Staudt,et al.  Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. , 2005, Blood.

[74]  Michael L. Wang,et al.  High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  E. Hoster,et al.  Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  M. Ghielmini,et al.  Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  E. Hoster,et al.  Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. , 2004, Blood.

[78]  R. Gascoyne,et al.  Limited-stage mantle-cell lymphoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.